Onset and maintenance of efficacy of subcutaneous tanezumab in patients with moderate to severe osteoarthritis of the knee or hip: A 16-week dose-titration study

Schnitzer, Thomas J.; Khan, Arifulla; Bessette, Louis; Davignon, Isabelle; Brown, Mark T.; Pixton, Glenn C.; Prucka, William R.; Tive, Leslie; Viktrup, Lars; West, Christine R.

doi:10.1016/j.semarthrit.2020.03.004

Cited by 15 publications

(25 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The early and sustained efficacy of tanezumab seen in the current study in patients enrolled in Europe and Japan is supported by a previous study in North America with primary endpoints at Week 16 (Schnitzer et al., 2020 ). Both studies showed greater improvement from baseline in WOMAC Pain, Physical Function and PGA‐OA scores (LS mean) at Week 16 for tanezumab compared with placebo.…”

Section: Discussionsupporting

confidence: 84%

“…Studies using intravenous administration of the nerve growth factor monoclonal antibody, tanezumab, showed early and sustained efficacy in patients with hip or knee OA (Brown et al, 2012(Brown et al, , 2013Lane et al, 2010;Spierings et al, 2013). A dose-titration study of subcutaneous tanezumab in patients in North America with hip or knee OA demonstrated efficacy within the first week that was generally sustained over a 16-week treatment period (Schnitzer et al, 2019(Schnitzer et al, , 2020.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?

Bérenbaum

Langford

Perrot

et al. 2021

European Journal of Pain

Self Cite

View full text Add to dashboard Cite

is the manufacturer of tanezumab, which is being investigated for the treatment of patients with chronic pain. The authors received no payment for the preparation of this manuscript. The salaried employees from Pfizer and Eli Lilly and Company included stock and/or stock options in their declarations. Manuscript authors from Pfizer contributed to the study design; data collection, management and interpretation of data; and the preparation, review and approval of the manuscript. Manuscript authors from Eli Lilly and Company contributed to the study design; interpretation of data and the preparation, review and approval of the manuscript.

show abstract

Section: Discussionsupporting

confidence: 84%

Section: Introductionmentioning

confidence: 99%

Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?

Bérenbaum

Langford

Perrot

et al. 2021

European Journal of Pain

Self Cite

View full text Add to dashboard Cite

show abstract

“…A few cases of RPOA and TJRs were observed. Similarly, in two different clinical trials, Schnitzer et al 50 , 51 showed that tanezumab improved all outcomes of patients with knee or hip OA. With regard to adverse effects, TJRs and RPOA were more evident in the tanezumab than in the placebo group, in a dose-dependent manner.…”

Section: Adverse Effects Of Anti-ngf Mab Therapy For Oa: An Update On the Clinical Trialsmentioning

confidence: 87%

The Role of Anti-Nerve Growth Factor Monoclonal Antibodies in the Control of Chronic Cancer and Non-Cancer Pain

Bimonte¹,

Cascella²,

Forte³

et al. 2021

JPR

View full text Add to dashboard Cite

Nerve growth factor (NGF) belongs to the neurotrophin family and plays a fundamental role in the endurance of sensory and sympathetic neurons during embryogenesis. NGF, by interacting with tropomyosin receptor kinase A receptor (TrkA), modulates the pain pathway through the enhancement of the neurotrophic and nociceptor functions. Moreover, it has been demonstrated that NGF is upregulated in patients with chronic pain syndromes, which are difficult to treat. Thus, new non-pharmacological approaches, based on the use of different species-specific monoclonal antibodies (mAbs) targeting the NGF pathway, have been tested for the treatment of chronic pain in preclinical and clinical studies. With regard to preclinical investigations, anti-NGF mAbs have been used for the management of osteoarthritis (OA) and chronic low back pain animal models, with encouraging results. Moreover, anti-NGF mAb therapy is effective in animal models of neuropathic cancer pain. As regards patients with OA, although phase II and phase III clinical trials with tanezumab led to pain reduction, the safety was not observed in all these patients. Here, we review the preclinical and clinical studies on anti-NGF mAb therapy in chronic syndromes, dissect the role of NGF in pain transduction, and highlight the use of anti-NGF mAbs in humans.

show abstract

“…Biological treatments that target OA, attenuate catabolic activity and promote articular cartilage repair include purified or recombinant growth factors, including fibroblast growth factor 18 (FGF-18), also known as Sprifermin [52][53][54], bone morphogenic protein 7 (BMP7) [55,56], transforming growth factor β1 (TGF-β1) [57][58][59], neuropeptides [60,61], humanized mAbs that target NGF and vascular endothelial growth factor (VEGF) (i.e., tanezumab (Pfizer) and fasinumab (Teva/Regeneron) against NGF and bevacizumab (Genentech/Roche) and ranibizumab (Genentech/Roche) against VEGF) [62][63][64][65][66], gene and cell therapy incorporating allogeneic cells and protein production platforms that overproduce produce growth factors (i.e., Kolon TissueGene's TissueGene-C, overproducing TGF-β1) [67][68][69][70][71] (Figure 2). A detailed discussion of each of these areas and intra-articular therapies is way beyond the scope of this communication and readers are directed to several comprehensive reviews [72][73][74][75].…”

Section: Emerging Biological Treatments For Oamentioning

confidence: 99%

Neuroscience and Neuroimmunology Solutions for Osteoarthritis Pain: Biological Drugs, Growth Factors, Peptides and Monoclonal Antibodies Targeting Peripheral Nerves

Mobasheri

2021

NeuroSci

View full text Add to dashboard Cite

Neuroscience is a vast discipline that deals with the anatomy, biochemistry, molecular biology, physiology and pathophysiology of central and peripheral nerves. Advances made through basic, translational, and clinical research in the field of neuroscience have great potential for long-lasting and beneficial impacts on human and animal health. The emerging field of biological therapy is intersecting with the disciplines of neuroscience, orthopaedics and rheumatology, creating new horizons for interdisciplinary and applied research. Biological drugs, growth factors, therapeutic peptides and monoclonal antibodies are being developed and tested for the treatment of painful arthritic and rheumatic diseases. This concise communication focuses on the solutions provided by the fields of neuroscience and neuroimmunology for real-world clinical problems in the field of orthopaedics and rheumatology, focusing on synovial joint pain and the emerging biological treatments that specifically target pathways implicated in osteoarthritis pain in peripheral nerves.

show abstract

Onset and maintenance of efficacy of subcutaneous tanezumab in patients with moderate to severe osteoarthritis of the knee or hip: A 16-week dose-titration study

Cited by 15 publications

References 12 publications

Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?

Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?

The Role of Anti-Nerve Growth Factor Monoclonal Antibodies in the Control of Chronic Cancer and Non-Cancer Pain

Neuroscience and Neuroimmunology Solutions for Osteoarthritis Pain: Biological Drugs, Growth Factors, Peptides and Monoclonal Antibodies Targeting Peripheral Nerves

Contact Info

Product

Resources

About